Meeting
2018 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).
Authors
Allan Andresson Lima Pereira
University of Texas MD Anderson Cancer Center, Houston, TX
Allan Andresson Lima Pereira , Michael Lam , Preeti Kanikarla Marie , Kanwal Pratap Singh Raghav , Van Karlyle Morris II, Hiromi Brown , Justin Windham , Dzifa Yawa Duose , Michael J. Overman , Eduardo Vilar Sanchez , Ignacio Ivan Wistuba , Peter Kipp , Filip Janku , Sudhir Sinha , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3533)
DOI
10.1200/JCO.2018.36.15_suppl.3533
Abstract #
3533
Poster Bd #
26
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Clinical and molecular assessment of response to regorafenib.
First Author: Nao Kakizawa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.
First Author: Anastasia Danilova
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler
Poster
2020 Gastrointestinal Cancers Symposium
A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.
First Author: Jingquan Jia